Browsing “Global PricingGlobal Pricing | EVERSANA”

Italy Tackles HTA, Pricing and Reimbursement Reforms

In July, new legislation set to overhaul the way pharmaceuticals are priced in Italy was finally implemented, following an announcement that dates all the way back to August 2019. The provision, which was signed by then Ministers Giulia Grillo (Health) and Giovanni Tria (Economy), has rolled out new criteria and methods by which the Italian […]

Trends in HTA Decisions

Alan Crowther and Dr. Magdi Stino explore trends in HTA decisions from the Pricentric HTA database for all therapeutic areas and within oncology. Examining over 25 HTA bodies from 2011 to 2019, they present findings on how decisions and ratings have changed over time, whether agencies are becoming more or less restrictive and the time to […]

At the COVID-19 Finish Line, How Do We Price The Winning Vaccine?

As of August 21, 2020, there were more than 165 potential vaccine candidates in development for the novel coronavirus. While some are still in preclinical stages, a handful are quickly making their way toward regulatory approval, meaning that pricing is starting to become an urgent reality. The first safety trials in humans started as early […]

Is BeNeLuxA Equipped for a Zolgensma Assessment?

The BeNeLuxA initiative is set to take on Zolgensma (onasemnogene abeparvovec), an innovative gene therapy for children under two years old with spinal muscular atrophy (SMA), which was granted conditional approval for use in Europe in May. Belgium, Ireland, and the Netherlands will undertake a joint health technology assessment (HTA) of Zolgensma as part of […]

Pricentric ONE Newsletter | June 2020

Good news, this month’s issue of the Pricentric Newsletter is now available for download. Fill out the form below to download the Newsletter!

What Canada’s IRP Changes Could Mean for the Industry

Last August, Canada’s Patented Medicine Prices Review Board (PMPRB) announced a set of amendments for its regulatory measures, in a bid to strengthen and modernize the country’s pricing framework for patented drugs. Following the initial proposal of the alterations, the PMPRB released its new draft guidelines in November 2019 and launched a 60-day consultation period […]

Pricentric ONE Newsletter | May 2020

Good news, this month’s issue of the Pricentric Newsletter is now available for download. Fill out the form below to download the Newsletter!

Pricentric ONE Newsletter | April 2020

Good news, this month’s issue of the Pricentric Newsletter is now available for download. Fill out the form below to download the Newsletter!

Is ICER Increasing Influence in the U.S. Over Time?

Recent high-profile product launches have reignited the debate on healthcare costs in the US. The Institute for Clinical and Economic Review (ICER) is an independent research organization that determines value-based price benchmarks. In a recent study, Dr. Stino, Product Manager, examined recent high-profile launches to understand the interaction between ICER value-based price benchmarks and actual […]

ICER’s Unsupported Price Increase Assessment

In October 2019, the Institute of Clinical and Economic Review (ICER) released their first annual report on Unsupported Price Increases of prescription drugs in the United States. The report takes a systematic approach to determine whether certain price increases are justified by new clinical evidence or other factors. Our Health Strategies Insights team conducted a […]